These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35585646)

  • 41. The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer.
    Jiang L; Huang J; Jiang S; Rong W; Shen Y; Li C; Tian Y; Ning J; Chen X; Yang Y; Ding Z; Li Z; Luo Q
    Cancer Immunol Immunother; 2021 Aug; 70(8):2313-2321. PubMed ID: 33512555
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.
    Cortellini A; Giusti R; Filetti M; Citarella F; Adamo V; Santini D; Buti S; Nigro O; Cantini L; Di Maio M; Aerts JGJV; Bria E; Bertolini F; Ferrara MG; Ghidini M; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Mazzoni F; Antonuzzo L; Gelibter A; Marchetti P; Chiari R; Macerelli M; Rastelli F; Della Gravara L; Gori S; Tuzi A; De Tursi M; Di Marino P; Mansueto G; Pecci F; Zoratto F; Ricciardi S; Migliorino MR; Passiglia F; Metro G; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G; Tiseo M; Russano M; Russo A; Pinato DJ
    J Hematol Oncol; 2022 Jan; 15(1):9. PubMed ID: 35062993
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
    van Wijk LM; Nilas AB; Vrieling H; Vreeswijk MPG
    Expert Rev Mol Diagn; 2022 Feb; 22(2):185-199. PubMed ID: 34913794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
    Fan Y; Ying H; Wu X; Chen H; Hu Y; Zhang H; Wu L; Yang Y; Mao B; Zheng L
    Cancer Biol Med; 2020 Nov; 17(4):1002-1013. PubMed ID: 33299649
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy.
    Kou F; Wu L; Zhu Y; Li B; Huang Z; Ren X; Yang L
    Cancer Gene Ther; 2022 Aug; 29(8-9):1153-1159. PubMed ID: 35022521
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer.
    Dai J; Jiang M; He K; Wang H; Chen P; Guo H; Zhao W; Lu H; He Y; Zhou C
    Front Oncol; 2021; 11():708294. PubMed ID: 34604048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
    Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB).
    Fridland S; Kim HS; Chae YK
    Transl Lung Cancer Res; 2024 Jul; 13(7):1481-1494. PubMed ID: 39118891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical significance of tumor mutation burden and DNA damage repair in advanced stage non-small cell lung cancer patients.
    Zhang H; Deng YM; Chen ZC; Tang YC; Yang S; Zhang SD; Liang JM; Wang YG; Wu X; Zhang RW; Feng WN
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7664-7672. PubMed ID: 32744692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms.
    Liu Z; Lin G; Yan Z; Li L; Wu X; Shi J; He J; Zhao L; Liang H; Wang W
    Front Immunol; 2022; 13():989275. PubMed ID: 36238300
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.
    Su PL; Chen JY; Chu CY; Chen YL; Chen WL; Lin KY; Ho CL; Tsai JS; Yang SC; Chen CW; Wu YL; Tseng YL; Chang CC; Yen YT; Lin CY; Lin CC; Su WC
    Sci Rep; 2022 Feb; 12(1):3319. PubMed ID: 35228655
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Shi Z; Shen J; Qiu J; Zhao Q; Hua K; Wang H
    Theranostics; 2021; 11(15):7175-7187. PubMed ID: 34158843
    [No Abstract]   [Full Text] [Related]  

  • 57. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
    Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
    Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes.
    Rosenbaum E; Jonsson P; Seier K; Qin LX; Chi P; Dickson M; Gounder M; Kelly C; Keohan ML; Nacev B; Donoghue MTA; Chiang S; Singer S; Ladanyi M; Antonescu CR; Hensley ML; Movva S; D'Angelo SP; Tap WD
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33283135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Ricciuti B; Recondo G; Spurr LF; Li YY; Lamberti G; Venkatraman D; Umeton R; Cherniack AD; Nishino M; Sholl LM; Shapiro GI; Awad MM; Cheng ML
    Clin Cancer Res; 2020 Aug; 26(15):4135-4142. PubMed ID: 32332016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.